User profiles for Eric A. Klein

Eric A. Klein

Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic
Verified email at ccf.org
Cited by 69985

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

SM Lippman, EA Klein, PJ Goodman, MS Lucia… - Jama, 2009 - jamanetwork.com
Context Secondary analyses of 2 randomized controlled trials and supportive epidemiologic
and preclinical data indicated the potential of selenium and vitamin E for preventing …

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

EA Klein, IM Thompson, CM Tangen, JJ Crowley… - Jama, 2011 - jamanetwork.com
Context The initial report of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
found no reduction in risk of prostate cancer with either selenium or vitamin E supplements …

[HTML][HTML] Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

MC Liu, GR Oxnard, EA Klein, C Swanton, MV Seiden… - Annals of …, 2020 - Elsevier
Background Early cancer detection could identify tumors at a time when outcomes are
superior and treatment is less morbid. This prospective case-control sub-study (from …

Task Group 142 report: Quality assurance of medical accelerators a

EE Klein, J Hanley, J Bayouth, FF Yin, W Simon… - Medical …, 2009 - Wiley Online Library
The task group (TG) for quality assurance of medical accelerators was constituted by the
American Association of Physicists in Medicine's Science Council under the direction of the …

A contemporary prostate cancer grading system: a validated alternative to the Gleason score

…, M Han, CA Reddy, JP Ciezki, T Nyberg, EA Klein - European urology, 2016 - Elsevier
Background Despite revisions in 2005 and 2014, the Gleason prostate cancer (PCa)
grading system still has major deficiencies. Combining of Gleason scores into a three-tiered …

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 …

…, L Herandez-Vazquez, SH Hsia, MR Jardula, EJ Klein… - The Lancet, 2021 - thelancet.com
Background We aimed to assess efficacy and safety, with a special focus on cardiovascular
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …

[HTML][HTML] Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

…, TM Pisansky, KM Slawin, EA Klein… - Journal of clinical …, 2007 - ncbi.nlm.nih.gov
Purpose An increasing serum prostate-specific antigen (PSA) level is the initial sign of
recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation …

[HTML][HTML] Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

EA Klein, D Richards, A Cohn, M Tummala… - Annals of …, 2021 - Elsevier
Background A multi-cancer early detection (MCED) test used to complement existing screening
could increase the number of cancers detected through population screening, potentially …

Predicting 15-year prostate cancer specific mortality after radical prostatectomy

…, DM Rabah, MW Kattan, C Yu, EA Klein… - The Journal of …, 2011 - auajournals.org
Purpose : Long-term prostate cancer specific mortality after radical prostatectomy is poorly
defined in the era of widespread screening. An understanding of the treated natural history of …

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling

EA Klein, MR Cooperberg, C Magi-Galluzzi, JP Simko… - European urology, 2014 - Elsevier
Background Prostate tumor heterogeneity and biopsy undersampling pose challenges to
accurate, individualized risk assessment for men with localized disease. Objective To identify …